Prevalence and global trends of polypharmacy in patients with chronic liver disease: A systematic review and meta-analysis.

In an examination of multiple community- and hospital-based databases of patients with CLD, we found a pooled prevalence estimate of polypharmacy of approximately 31%. This represents a case burden within the range reported in the general population and will likely respond to mitigation strategies employed thus far for patients in that population.